Nuvelo Announces First Quarter 2008 Financial Results and Updated 2008 Outlook Conference Call

Monday, April 28, 2008 General News
Email Print This Page Comment
Font : A-A+

SAN CARLOS, Calif., April 28 Nuvelo, Inc.(Nasdaq: NUVO) today announced that it will hold a conference call and virtualwebcast to discuss its first quarter 2008 financial results and provide anupdated outlook for 2008 on Thursday, May 8, at 4:30 p.m. Eastern Time(1:30 p.m. Pacific Time).

To participate in the conference call, please dial 866-854-8095 fordomestic callers and 706-634-8567 for international callers and referenceconference passcode 43639045. A telephone replay of the conference call willbe available through Thursday, May 22, 2008. To access the replay, please dial800-642-1687 for domestic callers and 706-645-9291 for international callersand reference conference passcode 43639045.

This call is being webcast by Thomson/CCBN and will include a virtualslide presentation. The webcast can be accessed via Nuvelo's website athttp://www.nuvelo.com and is also being distributed through the ThomsonStreetEvents Network. Individual investors can listen to the call athttp://www.earnings.com, Thomson's individual investor portal, powered byStreetEvents. Institutional investors can access the call via ThomsonStreetEvents (http://www.streetevents.com), a password-protected eventmanagement site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through thediscovery, development and commercialization of novel drugs for acutecardiovascular disease, cancer and other debilitating medical conditions.Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor inPhase 1 development for use as a potential short-acting anticoagulant duringmedical or surgical procedures; and preclinical candidate NU206, a Wnt pathwaymodulator for the potential treatment of chemotherapy/radiationtherapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelois pursuing research programs in leukemia and lymphoma therapeutic antibodiesand Wnt signaling pathway therapeutics to further expand its pipeline andcreate additional partnering and licensing opportunities.

Information about Nuvelo is available at our website athttp://www.nuvelo.com or by phoning 650-517-8000.

SOURCE Nuvelo, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook